We use cookies for a better user experience. Read our Privacy Policy

I Agree

Biobanking Market

Biobanking Market (Product: Equipment, Consumables, and Software & Services; Biospecimen Type: Blood Products, Human Tissues, Cell Lines, Nucleic Acids, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Biobanking Market Outlook 2031

  • The global biobanking market was valued at US$ 50.1 Bn in 2021
  • The global market is projected to grow at a CAGR of 5.9% from 2022 to 2031
  • The global biobanking market is anticipated to reach more than US$ 87.4 Bn by the end of 2031

Analysts’ Viewpoint on Biobanking Market Scenario

Biobanking represents a new and innovative research field that involves international infrastructure and governmental organizations, which help in the adoption of best practices and provide scientific, ethical, and legal guidelines for the industry and public health. Imaging biobanks connected to biological samples and patients' clinical data is a new area in biobanking. Biobanks can help create multi-omics biobanks, where findings from genomics, proteomics, and metabolomics could be combined with radiomic data to create a novel and individualized method of treating a disease. Biobanking is becoming more sophisticated, akin to any industry in its early stages of development. Automation will play a significant role in biobanking storage, as the movement toward centralization and standardization continues. The global biobanking market size is expected to be driven by the growth in demand for personalized medicine, which will broaden the applications of biospecimen to facilitate ground-breaking treatments in areas of complex disease in the next few years.

Biobanking Market

Biobanking Market Introduction

The term 'biobanking' is often misused to refer to any collection of human biological specimens (biospecimens), regardless of the standards established for various tissue collection procedures or requirements pertaining to ethical and legal considerations. The process of collecting bodily fluids or tissue samples for usage in research to better understand health and disease is referred to as biobanking. Biobank is a sizable collection of biospecimens that are kept primarily for usage in health and medical research, and are linked to pertinent personal and health data (such as electronic medical record, family history, lifestyle, and genetic information).

The National Centre for Advanced Research and Excellence in Heart Failure (CARE-HF) at SCTIMST was established by ICMR to expand research in the field, as heart failure emerged as a significant health issue in India. One of the project's key components is the Heart Failure Biobank, which received funding of US$ 85,000 to build cutting-edge storage facilities.

In terms of usage and design (focused on populations or diseases), biobanks are diverse (epidemiology, translational, pharmaceutical research). Biobanks include information and samples from large-scale epidemiologic collections, family studies, patients with a particular disease, clinical trials of novel treatments, or patients with the disease in question. Data and samples are invariably gathered according to various guidelines, standards, and objectives.

According to the biobanking market analysis, little standardization has taken place across biobanks due to the challenges of data collection and sample storage within studies. The field of biome biobank research is rapidly evolving; however, the necessary biobanking infrastructure is currently fragmented and unprepared for microbiome biobanking. A number of international initiatives and protocols have recently been developed to address this issue. The goal of procedure standardization and harmonization is to facilitate data sharing among various resources, increasing effective sample size and statistical power, particularly for rare diseases.

Request a sample to get extensive insights into the Biobanking Market

Public Participation in Biobanking to Drive Global Biobanking Market

Diversity of public participation in biobanking is a highlight of biobank success. Increase in number of biobanks across the world reflects their potential to improve the reproducibility and meaning of data generated by biomedical research. The fact that biospecimens are collected using strict and standardized methodologies ensures reproducibility, while meaningfulness is achieved by linking relevant information to biospecimens themselves as well as their donors. Biobanks' success is dependent on the participation of diverse groups of people.

Increase in funding for biobanking from private and government organizations and expansion of application areas of bio-banked samples are the major factors driving the global biobanking market size. Availability of government funding for regenerative medicine, stem cell therapeutics, and cell & gene therapy is encouraging research in this area. Furthermore, growth in trend of cord blood banking is expected to contribute to the growth of the market.

Future prospects, such as advancements in orthopedic procedures using stem cells, are expected to fuel the regenerative medicine market. Genomic research is a key driver of the global market. Government support for regenerative medicine research through various initiatives is also likely to increase biobanking market share.

Surge in Demand for Personalized Medicine Fueling Equipment Segment

Based on product, the equipment segment accounted for the largest share of the global biobanking market in 2021. Biobanking equipment is used in biorepositories to store biological samples for research purposes. Researchers use biobanking equipment to conduct tests or analyze specimens stored in a biobank. Along with equipment and consumables, software and services play an important role in assisting researchers in their studies of various diseases.

Surge in demand for personalized medicine, owing to high unmet medical requirements for developing effective therapies, is a key factor propelling the equipment segment. Increase in pharmaceutical R&D budgets by governments and private players is expected to support research activities. This is likely to augment the equipment segment.

Request a custom report on Biobanking Market

Usage in DNA and RNA Analyses Propelling Blood Products Segment

In terms of biospecimen type, the blood products segment held significant market share in 2021. Blood is one of the most frequently used biospecimens in research. Depending on the downstream application and blood fraction required, it is collected in tubes containing preservatives and additives (serum, plasma, white blood cells, red cells). Serum samples are typically collected in tubes containing a clot accelerator such as thrombin or silica, while plasma samples can be collected in tubes containing various anticoagulant additives. Majority of biochemical analyses are performed on serum, while DNA and RNA analyses are performed on anticoagulated blood. These practices have the potential to introduce heterogeneity into basic data. Citrate-stabilized blood, for example, yields higher DNA and RNA quality and more lymphocytes for culture than other anti-coagulants, while EDTA-coated collection tubes would be preferred for protein assays and most DNA-molecule analyses.

Growth in Trend of Precision Medicine Augmenting Therapeutics Segment

Based on application, the therapeutics segment is projected to account for major share of the global biobanking market during the forecast period. Clinical trials and research-based innovative activities such as personalized medicine aim to broaden the applications of biospecimens in research. Demand for precision medicines is high, as these promise breakthrough treatments in the most complex disease areas. Biobanks stand to benefit significantly from the growth in trend of precision medicines due to the sample data they possess, which is critical to precision medicine applications in therapy areas such as oncology, psychiatry, infectious diseases, and cardiology.

Institutes are conducting studies on the usage of cord blood in various areas of science that could benefit human health. The Lund University in Sweden launched the world's largest biobank in 2020 to better understand and conduct research in the most common diseases such as Alzheimer's, Parkinson's, cardiovascular disease, and diabetes. Hence, surge in research activities has been observed in cord blood applications in the past few years. This is expected to increase the demand for cord blood, which in turn, is likely to augment the therapeutics segment.

Advantages over Manual Sample Transport Bolstering Automated Segment

In terms of storage type, the automated segment is anticipated to grow at a rapid pace during the forecast period. Increase in demand for biobanking has induced biobanks to turn to automation to help maintain sample integrity and uphold their stringent specimen tracking standards. Automation can be used to improve access, cost, and throughput at various stages of the biobanking process.

Automated transport of biological samples from clinics and pre-analytical labs to the biobank has several advantages over manual sample transport. The primary advantage is the ability to deliver specimens 24 hours a day, seven days a week, without the need for staff to be present at all times, resulting in lower personnel costs. Moving samples around the lab can be aided by automated workstations.

In order to ensure consistent quality, the collection, processing, storage, and retrieval of samples by biobanks and biorepositories should be standardized, harmonized, and quality controlled to the highest level possible. This can be accomplished by putting in place a quality management system (QMS) and standard operating procedures (SOPs). Implementing technical solutions, particularly the automation of critical biobanking process areas, could help support this process. Automation improves reproducibility and accuracy, while decreasing the incidence of mislabeled or misplaced samples by reducing or eliminating human handling steps.

Regional Outlook of Global Biobanking Market

North America accounted for the largest share of the global biobanking market in 2021. The region is projected to be a highly lucrative market during the forecast period, with high market attractiveness index. This can be ascribed to the increase in adoption of advanced technologies and rise in awareness about biobanking among healthcare professionals and individuals working in the research and development industry. Furthermore, increase in R&D activities in the healthcare sector to develop novel biobanking and presence of major players are anticipated to drive the biobanking market in the region during the forecast period.

The market in Asia Pacific is expected to grow at a rapid pace from 2022 to 2031. This can be ascribed to the increase in geriatric population, which is more susceptible to chronic diseases; better health care infrastructure; and rise in demand for biospecimen products in the region.

Analysis of Key Players in Global Biobanking Market

The global biobanking market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global biobanking market. Thermo Fisher Scientific, Inc., PHC Holdings Corporation (Panasonic Healthcare), Hamilton Company, Chart Industries, Inc., VWR International, LLC, QIAGEN N.V., Greiner AG, Brooks Automation, Inc., Merck KGaA, and Tecan Trading AG are the prominent players operating in the global biobanking market.

Key Developments in Global Biobanking Market

  • In May 2022, BC Platforms (BCP), a healthcare data management and analytics company, announced a multi-year contract with three Hospital District owned Biobanks (Clinical Biobanks) in Finland to improve access to and automated management of phenotypic, genomic, and clinical data
  • In April 2020, Biogen collaborated with MA Health Organizations to launch COVID-19 Biobank. The company's employees and other close contacts helped coronavirus treatment efforts by donating blood samples and medical data to the COVID-19 biobank.

Each of these players has been profiled in the biobanking market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Biobanking Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 50.1 Bn

Market Forecast Value in 2031

More than US$ 87.4 Bn

Growth Rate

(CAGR)

5.9%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Equipment
    • Consumables
    • Software & Services
  • Biospecimen Type
    • Blood Products
    • Human Tissues
    • Cell Lines
    • Nucleic Acids
    • Others
  • Application
    • Therapeutics
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Others
  • Storage Type
    • Manual
    • Automated

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • PHC Holdings Corporation (Panasonic Healthcare)
  • Hamilton Company
  • Chart Industries, Inc.
  • VWR International LLC (Avantor, Inc.)
  • QIAGEN N.V.
  • Greiner AG
  • Brooks Automation, Inc.
  • Merck KGaA
  • Tecan Trading AG.
  • Micronic
  • Greiner Bio One
  • Biobank AS
  • Biokryo GmbH

Customization Scope

Available upon request

Pricing

Available upon request

Biobanking Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global biobanking market in 2021?

The global biobanking market was valued at US$ 50.1 Bn in 2021

How big will be the global biobanking market in 2031?

The global market is projected to reach more than US$ 87.4 Bn by 2031

What will be the CAGR of the global biobanking market during the forecast period (2022–2031)?

The global biobanking market is anticipated to grow at a CAGR of 5.9% from 2022 to 2031

Which are the prominent trends that affect market growth?

Advancements in biobanking and growth in trend of conserving cord blood stem cells of newborns are driving the global biobanking market

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global biobanking market during the forecast period

Who are the prominent players in the global biobanking market?

Thermo Fisher Scientific, Inc., Tecan Group Ltd., Qiagen N.V., Hamilton Company, Brooks Automation, TTP Labtech Ltd., VWR Corporation, Promega Corporation, Worthington Industries, Chart Industries, Becton, Dickinson and Company, and Merck KGaA

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biobanking Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Biobanking Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Technological Advancement

    5.2. List of Major Biobanks, by Region

    5.3. List of Vendors Supporting Automated Biobanking

    5.4. COVID-19 Impact Analysis

    5.5. Regulatory Scenario by Region/globally

6. Global Biobanking Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product, 2017–2031

        6.3.1. Equipment

            6.3.1.1. Temperature Control Systems

            6.3.1.2. Incubators & Centrifuges

            6.3.1.3. Alarms & Monitoring Systems

            6.3.1.4. Accessories & Other equipment

        6.3.2. Consumables

            6.3.2.1. Cryovials & Cryomolds

            6.3.2.2. Tubes

            6.3.2.3. Others

        6.3.3. Software & Services

    6.4. Market Attractiveness Analysis, by Product

7. Global Biobanking Market Analysis and Forecast, by Biospecimen Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Biospecimen Type, 2017–2031

        7.3.1. Blood Products

        7.3.2. Human Tissues

        7.3.3. Cell Lines

        7.3.4. Nucleic Acids

        7.3.5. Others

    7.4. Market Attractiveness Analysis, by Biospecimen Type

8. Global Biobanking Market Analysis and Forecast, by Application

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Application, 2017–2031

        8.3.1. Therapeutics

        8.3.2. Clinical Diagnostics

        8.3.3. Drug Discovery & Development

        8.3.4. Others

        8.3.5. Neuropathic Pain

        8.3.6. Others

    8.4. Market Attractiveness Analysis, by Application

9. Global Biobanking Market Analysis and Forecast, by Storage Product

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Storage Product, 2017–2031

        9.3.1. Manual

        9.3.2. Automated

    9.4. Market Attractiveness Analysis, by Storage Product

10. Global Biobanking Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Region

11. North America Biobanking Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product, 2017–2031

        11.2.1. Equipment

            11.2.1.1. Temperature Control Systems

            11.2.1.2. Incubators & Centrifuges

            11.2.1.3. Alarms & Monitoring Systems

            11.2.1.4. Accessories & Other equipment

        11.2.2. Consumables

            11.2.2.1. Cryovials & Cryomolds

            11.2.2.2. Tubes

            11.2.2.3. Others

        11.2.3. Software & Services

    11.3. Market Value Forecast, by Biospecimen Type, 2017–2031

        11.3.1. Blood Products

        11.3.2. Human Tissues

        11.3.3. Cell Lines

        11.3.4. Nucleic Acids

        11.3.5. Others

    11.4. Market Value Forecast, by Application, 2017–2031

        11.4.1. Therapeutics

        11.4.2. Clinical Diagnostics

        11.4.3. Drug Discovery & Development

        11.4.4. Others

        11.4.5. Neuropathic Pain

        11.4.6. Others

    11.5. Market Value Forecast, by Storage Product, 2017–2031

        11.5.1. Manual

        11.5.2. Automated

    11.6. Market Value Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Product

        11.7.2. By Biospecimen Type

        11.7.3. By Application

        11.7.4. By Storage Product

        11.7.5. By Country

12. Europe Biobanking Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product, 2017–2031

        12.2.1. Equipment

            12.2.1.1. Temperature Control Systems

            12.2.1.2. Incubators & Centrifuges

            12.2.1.3. Alarms & Monitoring Systems

            12.2.1.4. Accessories & Other equipment

        12.2.2. Consumables

            12.2.2.1. Cryovials & Cryomolds

            12.2.2.2. Tubes

            12.2.2.3. Others

        12.2.3. Software & Services

    12.3. Market Value Forecast, by Biospecimen Type, 2017–2031

        12.3.1. Blood Products

        12.3.2. Human Tissues

        12.3.3. Cell Lines

        12.3.4. Nucleic Acids

        12.3.5. Others

    12.4. Market Value Forecast, by Application, 2017–2031

        12.4.1. Therapeutics

        12.4.2. Clinical Diagnostics

        12.4.3. Drug Discovery & Development

        12.4.4. Others

        12.4.5. Neuropathic Pain

        12.4.6. Others

    12.5. Market Value Forecast, by Storage Product, 2017–2031

        12.5.1. Manual

        12.5.2. Automated

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Product

        12.7.2. By Biospecimen Type

        12.7.3. By Application

        12.7.4. By Storage Product

        12.7.5. By Country/Sub-region

13. Asia Pacific Biobanking Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product, 2017–2031

        13.2.1. Equipment

            13.2.1.1. Temperature Control Systems

            13.2.1.2. Incubators & Centrifuges

            13.2.1.3. Alarms & Monitoring Systems

            13.2.1.4. Accessories & Other equipment

        13.2.2. Consumables

            13.2.2.1. Cryovials & Cryomolds

            13.2.2.2. Tubes

            13.2.2.3. Others

        13.2.3. Software & Services

    13.3. Market Value Forecast, by Biospecimen Type, 2017–2031

        13.3.1. Blood Products

        13.3.2. Human Tissues

        13.3.3. Cell Lines

        13.3.4. Nucleic Acids

        13.3.5. Others

    13.4. Market Value Forecast, by Application, 2017–2031

        13.4.1. Therapeutics

        13.4.2. Clinical Diagnostics

        13.4.3. Drug Discovery & Development

        13.4.4. Others

        13.4.5. Neuropathic Pain

        13.4.6. Others

    13.5. Market Value Forecast, by Storage Product, 2017–2031

        13.5.1. Manual

        13.5.2. Automated

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Product

        13.7.2. By Biospecimen Type

        13.7.3. By Application

        13.7.4. By Storage Product

        13.7.5. By Country/Sub-region

14. Latin America Biobanking Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Product, 2017–2031

        14.2.1. Equipment

            14.2.1.1. Temperature Control Systems

            14.2.1.2. Incubators & Centrifuges

            14.2.1.3. Alarms & Monitoring Systems

            14.2.1.4. Accessories & Other equipment

        14.2.2. Consumables

            14.2.2.1. Cryovials & Cryomolds

            14.2.2.2. Tubes

            14.2.2.3. Others

        14.2.3. Software & Services

    14.3. Market Value Forecast, by Biospecimen Type, 2017–2031

        14.3.1. Blood Products

        14.3.2. Human Tissues

        14.3.3. Cell Lines

        14.3.4. Nucleic Acids

        14.3.5. Others

    14.4. Market Value Forecast, by Application, 2017–2031

        14.4.1. Therapeutics

        14.4.2. Clinical Diagnostics

        14.4.3. Drug Discovery & Development

        14.4.4. Others

        14.4.5. Neuropathic Pain

        14.4.6. Others

    14.5. Market Value Forecast, by Storage Product, 2017–2031

        14.5.1. Manual

        14.5.2. Automated

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Product

        14.7.2. By Biospecimen Type

        14.7.3. By Application

        14.7.4. By Storage Product

        14.7.5. By Country/Sub-region

15. Middle East & Africa Biobanking Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Product, 2017–2031

        15.2.1. Equipment

            15.2.1.1. Temperature Control Systems

            15.2.1.2. Incubators & Centrifuges

            15.2.1.3. Alarms & Monitoring Systems

            15.2.1.4. Accessories & Other equipment

        15.2.2. Consumables

            15.2.2.1. Cryovials & Cryomolds

            15.2.2.2. Tubes

            15.2.2.3. Others

        15.2.3. Software & Services

    15.3. Market Value Forecast, by Biospecimen Type, 2017–2031

        15.3.1. Blood Products

        15.3.2. Human Tissues

        15.3.3. Cell Lines

        15.3.4. Nucleic Acids

        15.3.5. Others

    15.4. Market Value Forecast, by Application, 2017–2031

        15.4.1. Therapeutics

        15.4.2. Clinical Diagnostics

        15.4.3. Drug Discovery & Development

        15.4.4. Others

        15.4.5. Neuropathic Pain

        15.4.6. Others

    15.5. Market Value Forecast, by Storage Product, 2017–2031

        15.5.1. Manual

        15.5.2. Automated

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Product

        15.7.2. By Biospecimen Type

        15.7.3. By Application

        15.7.4. By Storage Product

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competitive Matrix (by tier and size of companies)

    16.2. Market Share Analysis, by Company (2021)

    16.3. Company Profiles

        16.3.1. Thermo Fisher Scientific, Inc.

            16.3.1.1. Company Overview

            16.3.1.2. Product Portfolio

            16.3.1.3. SWOT Analysis

            16.3.1.4. Financial Overview

            16.3.1.5. Strategic Overview

        16.3.2. PHC Holdings Corporation (Panasonic Healthcare)

            16.3.2.1. Company Overview

            16.3.2.2. Product Portfolio

            16.3.2.3. SWOT Analysis

            16.3.2.4. Financial Overview

            16.3.2.5. Strategic Overview

        16.3.3. Hamilton Company

            16.3.3.1. Company Overview

            16.3.3.2. Product Portfolio

            16.3.3.3. SWOT Analysis

            16.3.3.4. Financial Overview

            16.3.3.5. Strategic Overview

        16.3.4. Chart Industries, Inc.

            16.3.4.1. Company Overview

            16.3.4.2. Product Portfolio

            16.3.4.3. SWOT Analysis

            16.3.4.4. Financial Overview

            16.3.4.5. Strategic Overview

        16.3.5. VWR International

            16.3.5.1. Company Overview

            16.3.5.2. Product Portfolio

            16.3.5.3. SWOT Analysis

            16.3.5.4. Financial Overview

            16.3.5.5. Strategic Overview

        16.3.6. LLC (Avantor, Inc.)

            16.3.6.1. Company Overview

            16.3.6.2. Product Portfolio

            16.3.6.3. SWOT Analysis

            16.3.6.4. Financial Overview

            16.3.6.5. Strategic Overview

        16.3.7. QIAGEN N.V.

            16.3.7.1. Company Overview

            16.3.7.2. Product Portfolio

            16.3.7.3. SWOT Analysis

            16.3.7.4. Financial Overview

            16.3.7.5. Strategic Overview

        16.3.8. Greiner AG

            16.3.8.1. Company Overview

            16.3.8.2. Product Portfolio

            16.3.8.3. SWOT Analysis

            16.3.8.4. Financial Overview

            16.3.8.5. Strategic Overview

        16.3.9. Brooks Automation, Inc.

            16.3.9.1. Company Overview

            16.3.9.2. Product Portfolio

            16.3.9.3. SWOT Analysis

            16.3.9.4. Financial Overview

            16.3.9.5. Strategic Overview

        16.3.10. Merck KGaA

            16.3.10.1. Company Overview

            16.3.10.2. Product Portfolio

            16.3.10.3. SWOT Analysis

            16.3.10.4. Financial Overview

            16.3.10.5. Strategic Overview

        16.3.11. Tecan Trading AG.

            16.3.11.1. Company Overview

            16.3.11.2. Product Portfolio

            16.3.11.3. SWOT Analysis

            16.3.11.4. Financial Overview

            16.3.11.5. Strategic Overview

        16.3.12. Micronic

            16.3.12.1. Company Overview

            16.3.12.2. Product Portfolio

            16.3.12.3. SWOT Analysis

            16.3.12.4. Financial Overview

            16.3.12.5. Strategic Overview

        16.3.13. Greiner Bio One

            16.3.13.1. Company Overview

            16.3.13.2. Product Portfolio

            16.3.13.3. SWOT Analysis

            16.3.13.4. Financial Overview

            16.3.13.5. Strategic Overview

        16.3.14. Biobank AS

            16.3.14.1. Company Overview

            16.3.14.2. Product Portfolio

            16.3.14.3. SWOT Analysis

            16.3.14.4. Financial Overview

            16.3.14.5. Strategic Overview

        16.3.15. Biokryo GmbH

            16.3.15.1. Company Overview

            16.3.15.2. Product Portfolio

            16.3.15.3. SWOT Analysis

            16.3.15.4. Financial Overview

            16.3.15.5. Strategic Overview

List of Tables

Table 01: Global Biobanking Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 02: Global Biobanking Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017–2031

Table 04: Global Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017–2031

Table 05: Global Biobanking Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Biobanking Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Biobanking Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 08: North America Biobanking Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 09: North America Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017–2031

Table 10: North America Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017–2031

Table 11: Europe Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Biobanking Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 13: Europe Biobanking Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 14: Europe Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017–2031

Table 15: Europe Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017–2031

Table 16: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 18: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 19: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017–2031

Table 20: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017–2031

Table 21: Latin America Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Biobanking Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 23: Latin America Biobanking Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Latin America Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017–2031

Table 25: Latin America Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017–2031

Table 26: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Product, 2017–2031

Table 28: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 29: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017–2031

Table 30: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017–2031

List of Figures

Figure 01: Global Biobanking Market Size (US$ Mn) and Distribution (%), by Region, 2021 and 2031

Figure 02: Global Biobanking Market Revenue (US$ Mn), by Product, 2021

Figure 03: Global Biobanking Market Value Share, by Product, 2021

Figure 04: Global Biobanking Market Value Share, by Application, 2021

Figure 05: Global Biobanking Market Value Share, by Biospecimen Type, 2021

Figure 06: Global Biobanking Market Value Share, by Storage Type, 2021

Figure 07: Global Biobanking Market Value Share, by Region, 2021

Figure 08: Global Biobanking Market Value (US$ Mn) Forecast, 2017–2031

Figure 09: Global Biobanking Market Value Share Analysis, by Product, 2017 and 2031

Figure 10: Global Biobanking Market Attractiveness Analysis, by Product, 2022–2031

Figure 11: Global Biobanking Market Value Share Analysis, by Application, 2017 and 2031

Figure 12: Global Biobanking Market Attractiveness Analysis, by Application, 2022–2031

Figure 13: Global Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031

Figure 14: Global Biobanking Market Attractiveness Analysis, by Storage type, 2022–2031

Figure 15: Global Biobanking Market Value Share Analysis, by Storage Type, 2017 and 2031

Figure 16: Global Biobanking Market Value Share Analysis, by Region, 2017 and 2031

Figure 17: Global Biobanking Market Attractiveness Analysis, by Region, 2022–2031

Figure 18: North America Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Biobanking Market Attractiveness Analysis, by Country, 2017–2031

Figure 20: North America Biobanking Market Value Share Analysis, by Country, 2017 and 2031

Figure 21: North America Biobanking Market Value Share Analysis, by Product, 2017 and 2031

Figure 22: North America Biobanking Market Value Share Analysis, by Application, 2017 and 2031

Figure 23: North America Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031

Figure 24: North America Biobanking Market Value Share Analysis, by Storage Type, 2017 and 2031

Figure 25: North America Biobanking Market Attractiveness Analysis, by Product, 2022–2031

Figure 26: North America Biobanking Market Attractiveness Analysis, by Application, 2022–2031

Figure 27: North America Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022–2031

Figure 28: North America Biobanking Market Attractiveness Analysis, by Storage Type, 2022–2031

Figure 29: Europe Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 30: Europe Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 31: Europe Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 32: Europe Biobanking Market Value Share Analysis, by Product, 2017 and 2031

Figure 33: Europe Biobanking Market Value Share Analysis, by Application, 2017 and 2031

Figure 34: Europe Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031

Figure 35: Europe Biobanking Market Value Share Analysis, by Storage Type, 2022–2031

Figure 36: Europe Biobanking Market Attractiveness Analysis, by Product, 2022–2031

Figure 37: Europe Biobanking Market Attractiveness Analysis, by Application, 2022–2031

Figure 38: Europe Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022–2031

Figure 39: Europe Biobanking Market Attractiveness Analysis, by Storage Type, 2022–2031

Figure 40: Asia Pacific Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 41: Asia Pacific Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 42: Asia Pacific Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 43: Asia Pacific Biobanking Market Value Share Analysis, by Product, 2017 and 2031

Figure 44: Asia Pacific Biobanking Market Value Share Analysis, by Application, 2017 and 2031

Figure 45: Asia Pacific Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031

Figure 46: Asia Pacific Biobanking Market Value Share Analysis, by Storage Type, 2022–2031

Figure 47: Asia Pacific Biobanking Market Attractiveness Analysis, by Product, 2022–2031

Figure 48: Asia Pacific Biobanking Market Attractiveness Analysis, by Application, 2022–2031

Figure 49: Asia Pacific Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022–2031

Figure 50: Asia Pacific Biobanking Market Attractiveness Analysis, by Storage Type, 2022–2031

Figure 51: Latin America Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 52: Latin America Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 53: Latin America Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 54: Latin America Biobanking Market Value Share Analysis, by Product, 2017 and 2031

Figure 55: Latin America Biobanking Market Value Share Analysis, by Application, 2017 and 2031

Figure 56: Latin America Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031

Figure 57: Latin America Biobanking Market Value Share Analysis, by Storage Type, 2022–2031

Figure 58: Latin America Biobanking Market Attractiveness Analysis, by Product, 2022–2031

Figure 59: Latin America Biobanking Market Attractiveness Analysis, by Application, 2022–2031

Figure 60: Latin America Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022–2031

Figure 61: Latin America Biobanking Market Attractiveness Analysis, by Storage Type, 2022–2031

Figure 62: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 63: Middle East & Africa Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 64: Middle East & Africa Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 65: Middle East & Africa Biobanking Market Value Share Analysis, by Product, 2017 and 2031

Figure 66: Middle East & Africa Biobanking Market Value Share Analysis, by Application, 2017 and 2031

Figure 67: Middle East & Africa Biobanking Market Value Share Analysis, by Storage Type, 2017 and 2031

Figure 68: Middle East & Africa Biobanking Market Attractiveness Analysis, by Product, 2022–2031

Figure 69: Middle East & Africa Biobanking Market Attractiveness Analysis, by Application, 2022–2031

Figure 70: Middle East & Africa Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022–2031

Figure 71: Middle East & Africa Biobanking Market Attractiveness Analysis, by Storage Type, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

625

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved